SABR.ENO.20.04.0494 – Abril/2020

REFERÊNCIAS

  1. Weill-Engerer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A, et al.

    Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study.

    J Am Geriatr Soc. 2004 Aug;52(8):1299-304.

  2. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, et al.

    Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.

    Ann Intern Med. 2010 Jul 6;153(1):8-18.

  3. Samama MM.

    An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.

    Arch Intern Med. 2000 Dec 11-25;160(22):3415-20.

  4. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, et al.; RIETE Investigators.

    The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients.

    Findings from the RIETE registry. J Thromb Haemost. 2004 Nov;2(11):1892-8.

  5. Vasco B, Villalba JC, Lopez-Jimenez L, Falga C, Montes J, Trujillo-Santos J, et al.; RIETE Investigators.

    Venous thromboembolism in nonagenarians. Findings from the RIETE Registry.

    Thromb Haemost. 2009 Jun;101(6):1112-8.

  6. Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, et al.; IMPROVE Investigators.

    Predictive and associative models to identify hospitalized medical patients at risk for VTE.

    Chest. 2011 Sep;140(3):706-14.

  7. Lechler E, Schramm W, Flosbach CW.

    The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin).

    The Prime Study Group. Haemostasis. 1996;26 Suppl 2:49-56.

  8. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW; THE-PRINCE Study Group.

    Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.

    Am Heart J. 2003 Apr;145(4):614-21.

  9. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group.

    Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.

    Circulation. 2004 Aug 17;110(7):874-9.

  10. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al.; ARTEMIS Investigators.

    Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

    BMJ. 2006 Feb 11;332(7537):325-9.

  11. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al.

    A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients.

    Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793-800.

  12. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, et al.

    Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.

    J Thromb Thrombolysis. 2011 May;31(4):407-16.

  13. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al.; ADOPT Trial Investigators.

    pixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

    N Engl J Med. 2011 Dec 8;365(23):2167-77.

  14. Rocha AT, Paiva EF, Lichtenstein A, Milani R Jr, Cavalheiro CF, Maffei FH.

    Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

    Vasc Health Risk Manag. 2007;3(4):533-53.

  15. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al.

    A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

    J Thromb Haemost. 2010 Nov;8(11):2450-7.

  16. Amin AN, Girard F, Samama MM.

    Does ambulation modify venous thromboembolism risk in acutely ill medical patients?

    Thromb Haemost. 2010 Nov;104(5):955-61.

  17. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ.

    Venous thromboembolism in the outpatient setting.

    Arch Intern Med. 2007 Jul 23;167(14):1471-5.

  18. Amin A, Lin J, Ryan A.

    Lack of thromboprophylaxis across the care continuum in US medical patients.

    Hosp Pract (1995). 2010 Jun;38(3):17-25.